Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to
sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required
on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain
global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the
levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact
on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«It was remarkable how we were able to examine this question
on a
global level, thanks to the
sustained efforts of many programs and individuals.»
«Warming greater than 2 degrees Celsius above 19th - century
levels is projected to be disruptive, reducing
global agricultural productivity, causing widespread loss of biodiversity and — if
sustained over centuries — melting much of the Greenland ice sheet with ensuing rise in sea
levels of several meters,» the AGU declares in its first statement in four years
on «Human Impacts
on Climate.»
On the other hand, while
sustained high oil prices could provide climate change mitigation efforts a mild boost, the study concludes that such market developments would be no substitute for concerted
global policy to limit climate change to below 2 °C above preindustrial
levels.
With humanity's ecological footprint of 2.7
global hectares (gha) per person means to say that to
sustain the current population
on Earth of 7 billion people would take 18.9 billion gha (2.7 gha x 7 billion people) which is higher than the 13.4 billion
global hectares (gha) of biologically productive land and water
on Earth, a fact that indicates that already exceeded the regenerative capacity of the planet in the average
level of current world consumption.
Since
global equity markets hit a high
on 25 January 2018, they have struggled to
sustain that
level, at the end of April 2018, the market is still down -6 % since those highs.
Panelists will discuss and assess the current political landscape
on global, national and regional
levels and share «tools» regarding art production, political action and
sustaining our communities and ourselves.
The long - term sea
level rise will depend critically
on the cumulative carbon emission pathway humans follow, which determines the
sustained global warming that can be maintained for centuries to millennia.
Communities will become self
sustaining, interrelated in a sustainable manner that organically is unified
on a
global level.
Estimates of CO2
level and average
global temperature trajectory (no
sustained temperature change) for the last 500 million years is evidence CO2 has no effect
on climate.
Carbon trading is not sufficient
on its own to achieve the Paris climate goals but equally we will not slash emissions to the
level required under Paris without a much more concerted and
sustained global take - up of carbon pricing.